These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

583 related items for PubMed ID: 17554963

  • 1. [Bioequivalence studies of pharmaceutical preparations].
    Vetchý D, Frýbortová K, Rabisková M, Danecková H.
    Cas Lek Cesk; 2007; 146(5):431-3. PubMed ID: 17554963
    [Abstract] [Full Text] [Related]

  • 2. Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration.
    Davit BM, Nwakama PE, Buehler GJ, Conner DP, Haidar SH, Patel DT, Yang Y, Yu LX, Woodcock J.
    Ann Pharmacother; 2009 Oct; 43(10):1583-97. PubMed ID: 19776300
    [Abstract] [Full Text] [Related]

  • 3. Types of bioequivalence and related statistical considerations.
    Hauck WW, Anderson S.
    Int J Clin Pharmacol Ther Toxicol; 1992 May; 30(5):181-7. PubMed ID: 1592546
    [Abstract] [Full Text] [Related]

  • 4. United States Food and Drug Administration requirements for approval of generic drug products.
    Meyer MC.
    J Clin Psychiatry; 2001 May; 62 Suppl 5():4-9; discussion 23-4. PubMed ID: 11305846
    [Abstract] [Full Text] [Related]

  • 5. Generic substitution: the use of medicinal products containing different salts and implications for safety and efficacy.
    Verbeeck RK, Kanfer I, Walker RB.
    Eur J Pharm Sci; 2006 May; 28(1-2):1-6. PubMed ID: 16413762
    [Abstract] [Full Text] [Related]

  • 6. Variability and impact on design of bioequivalence studies.
    Van Peer A.
    Basic Clin Pharmacol Toxicol; 2010 Mar; 106(3):146-53. PubMed ID: 20041877
    [Abstract] [Full Text] [Related]

  • 7. Bioequivalence studies: single vs multiple dose.
    Steinijans VW, Sauter R, Jonkman JH, Schulz HU, Stricker H, Blume H.
    Int J Clin Pharmacol Ther Toxicol; 1992 Mar; 30 Suppl 1():S31-6. PubMed ID: 1601529
    [Abstract] [Full Text] [Related]

  • 8. Investigation on the need of multiple dose bioequivalence studies for prolonged-release generic products.
    García-Arieta A, Morales-Alcelay S, Herranz M, de la Torre-Alvarado JM, Blázquez-Pérez A, Suárez-Gea ML, Alvarez C.
    Int J Pharm; 2012 Feb 28; 423(2):321-5. PubMed ID: 22120644
    [Abstract] [Full Text] [Related]

  • 9. Debate: Substitution of generic drugs in epilepsy: is there cause for concern?
    Gidal BE, Tomson T.
    Epilepsia; 2008 Dec 28; 49 Suppl 9():56-62. PubMed ID: 19087118
    [Abstract] [Full Text] [Related]

  • 10. Evaluating the bioavailability and bioequivalence of generic medications.
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2010 Jan 28; 48(1):13-6. PubMed ID: 20102127
    [Abstract] [Full Text] [Related]

  • 11. Quantitative assessment of the switchability of generic products.
    Karalis V, Bialer M, Macheras P.
    Eur J Pharm Sci; 2013 Nov 20; 50(3-4):476-83. PubMed ID: 23981332
    [Abstract] [Full Text] [Related]

  • 12. What makes a generic medication generic?
    Howland RH.
    J Psychosoc Nurs Ment Health Serv; 2009 Dec 20; 47(12):17-20. PubMed ID: 20000278
    [Abstract] [Full Text] [Related]

  • 13. Bioequivalence, antibacterial activity and therapeutic outcome of a generic meropenem (Mapenem).
    Leelarasamee A, Rongrungruang Y, Trakulsomboon S, Pongpech P, Thanawattanawanich P, Jithavech P.
    J Med Assoc Thai; 2008 Jul 20; 91(7):980-8. PubMed ID: 18839835
    [Abstract] [Full Text] [Related]

  • 14. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Bialer M.
    Epilepsia; 2007 Oct 20; 48(10):1825-32. PubMed ID: 17850324
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. [Bioequivalence and generic drugs. I. Studies of bioequivalence, considering the theoretical basis, design and use].
    Zapater P, Horga JF.
    Rev Neurol; 2007 Oct 20; 29(12):1235-46. PubMed ID: 10652753
    [Abstract] [Full Text] [Related]

  • 17. Bioequivalence and narrow therapeutic index drugs.
    Benet LZ, Goyan JE.
    Pharmacotherapy; 1995 Oct 20; 15(4):433-40. PubMed ID: 7479195
    [Abstract] [Full Text] [Related]

  • 18. Differentiating low-molecular-weight heparins based on chemical, biological, and pharmacologic properties: implications for the development of generic versions of low-molecular-weight heparins.
    Jeske WP, Walenga JM, Hoppensteadt DA, Vandenberg C, Brubaker A, Adiguzel C, Bakhos M, Fareed J.
    Semin Thromb Hemost; 2008 Feb 20; 34(1):74-85. PubMed ID: 18393144
    [Abstract] [Full Text] [Related]

  • 19. Alternative confidence intervals for the assessment of bioequivalence in four-period cross-over designs.
    Quiroz J, Ting N, Wei GC, Burdick RK.
    Stat Med; 2002 Jul 15; 21(13):1825-47. PubMed ID: 12111892
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 30.